Simufilam

CAT: 0804-HY-139142-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-139142-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam can be used for research of Alzheimer's disease[1][2][3].
CAS Number
[1224591-33-6]
Product Name Alternative
PTI-125
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Amyloid-β; iGluR; mTOR; Tau Protein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling; PI3K/Akt/mTOR
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/simufilam.html
Purity
98.08
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N(CC2=CC=CC=C2)C3(CCN(C)CC3)NC1
Molecular Formula
C15H21N3O
Molecular Weight
259.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Wang HY, et al. Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer's disease patient lymphocytes. Front Aging. 2023 Jun 29;4:1175601.|[2]Wang HY, et al. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012 Jul 18;32 (29) :9773-84.|[3]Wang HY, et al. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. Neurobiol Aging. 2017 Jul;55:99-114.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
MBS5803359Simufilam hydrochloride
E0077-25mgSimufilam
C01053-01Simufilam dihydrochloride

Popular Products